Multiple myeloma (MM) is the second most common hematologic malignancy and remains incurable despite the advent of numerous new drugs such as proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), and monoclonal antibodies. There is an unmet need to develop novel therapies for refractory/relapsed MM. In the past few years, chimeric antigen receptor (CAR)-modified T cell therapy for MM has shown promising efficacy in preclinical and clinical studies. Furthermore, the toxicities of CAR-T cell therapy are manageable. This article summarizes recent developments of CAR-T therapy in MM, focusing on promising targets, new technologies, and new research areas. Additionally, a comprehensive overview of antigen selection is presented along with preliminary results and future directions of CAR-T therapy development.

中文翻译：

---

嵌合抗原受体T细胞疗法可治疗多发性骨髓瘤。

多发性骨髓瘤（MM）是第二常见的血液系统恶性肿瘤，尽管出现了许多新药，例如蛋白酶体抑制剂（PIs），免疫调节剂（IMiDs）和单克隆抗体，但仍无法治愈。对于开发难治性/复发性MM的新疗法存在未满足的需求。在过去的几年中，嵌合抗原受体（CAR）修饰的MM T细胞疗法在临床前和临床研究中显示出有希望的疗效。此外，CAR-T细胞疗法的毒性是可以控制的。本文总结了MM中CAR-T疗法的最新发展，重点关注有希望的靶标，新技术和新研究领域。此外，还介绍了抗原选择的全面概述，以及CAR-T治疗发展的初步结果和未来方向。